KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) FCF Margin (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of FCF Margin data on record, last reported at 13.33% in Q4 2025.

  • For Q4 2025, FCF Margin fell 76.0% year-over-year to 13.33%; the TTM value through Dec 2025 reached 8.94%, up 24.0%, while the annual FY2025 figure was 8.94%, 24.0% up from the prior year.
  • FCF Margin reached 13.33% in Q4 2025 per AMRX's latest filing, down from 13.53% in the prior quarter.
  • Across five years, FCF Margin topped out at 27.65% in Q1 2021 and bottomed at 23.34% in Q2 2022.
  • Average FCF Margin over 5 years is 8.23%, with a median of 12.29% recorded in 2023.
  • Peak YoY movement for FCF Margin: crashed -4790bps in 2021, then surged 2612bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 8.52% in 2021, then crashed by -167bps to 5.7% in 2022, then soared by 458bps to 20.42% in 2023, then plummeted by -31bps to 14.09% in 2024, then decreased by -5bps to 13.33% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 13.33% in Q4 2025, 13.53% in Q3 2025, and 8.42% in Q2 2025.